Things are looking up for the Life Sciences industry as 2023 saw an increase in novel drug #approvals, M&A activity, R&D spending!

#Dealmaking activity in 2023 was brighter than expected, with deals worth $163 Bn announced in the year, a staggering 35% growth over 2022. Increased collaboration between Pharma and Tech companies and #growth in Pharmaceutical R&D spending is testament to the industry’s focus on #innovation, as they aim to bring about speed, scale and affordability.

Healthark Insights’ 4th report titled “Top 10 Life Sciences Trends of 2023” presents a list of top 10 such trends that have influenced the industry’s dynamics in the past year – check out the complete report!